FLT3-TKD Measurable Residual Disease Detection Using Droplet Digital PCR and Clinical Applications in Acute Myeloid Leukemia
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25115771 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Eric Wenlong Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Neoplasm, Residual, Leukemia, Myeloid, Acute, Polymerase Chain Reaction. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sydney Blood Cancer Research Institute.
Abstract (Originalsprache)
The tyrosine kinase domain of the FMS-Like tyrosine kinase 3 (FLT3-TKD) is recurrently mutated in acute myeloid leukemia (AML). Common molecular techniques used in its detection include PCR and capillary electrophoresis, Sanger sequencing and next-generation sequencing with recognized sensitivity limitations. This study aims to validate the use of droplet digital PCR (ddPCR) in the detection of measurable residual disease (MRD) involving the common FLT3-TKD mutations (D835Y, D835H, D835V, D835E). Twenty-two diagnostic samples, six donor controls, and a commercial D835Y positive control were tested using a commercial Bio-rad® ddPCR assay. All known variants were identified, and no false positives were detected in the wild-type control (100% specificity and sensitivity). The assays achieved a limit of detection suitable for MRD testing at 0.01% variant allelic fraction. Serial samples from seven intensively-treated patients with FLT3-TKD variants at diagnosis were tested. Five patients demonstrated clearance of FLT3-TKD clones, but two patients had FLT3-TKD persistence in the context of primary refractory disease. In conclusion, ddPCR is suitable for the detection and quantification of FLT3-TKD mutations in the MRD setting; however, the clinical significance and optimal management of MRD positivity require further exploration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Hematology, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.
- Molecular Hematology Laboratory, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.
- Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2050, Australia.
- Department of Hematology, St Vincent's Hospital, Sydney, NSW 2010, Australia.
- Department of Hematology, Royal North Shore Hospital, Sydney, NSW 2065, Australia.
ORCID-Profile: Eric Wenlong Li, Michael Krigstein
Förderung
- Sydney Blood Cancer Research Institute
Zitieren
APA
Li, E. W., Tran, N. Y. K., McCulloch, D., Krigstein, M., Catalano, A., Othman, J., Abadir, E., Smith, C., & Iland, H. (2024). FLT3-TKD Measurable Residual Disease Detection Using Droplet Digital PCR and Clinical Applications in Acute Myeloid Leukemia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25115771
Vancouver
Li EW, Tran NYK, McCulloch D, Krigstein M, Catalano A, Othman J, et al. FLT3-TKD Measurable Residual Disease Detection Using Droplet Digital PCR and Clinical Applications in Acute Myeloid Leukemia. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25115771
BibTeX
@article{Li2024,
author = {Li, Eric Wenlong and Tran, Ngoc Yen Kim and McCulloch, Derek and Krigstein, Michael and Catalano, Alberto and Othman, Jad and Abadir, Edward and Smith, Cheryl and Iland, Harry},
title = {FLT3-TKD Measurable Residual Disease Detection Using Droplet Digital PCR and Clinical Applications in Acute Myeloid Leukemia},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25115771}
}
EUVIMED